RU2693465C9 - Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания - Google Patents

Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания Download PDF

Info

Publication number
RU2693465C9
RU2693465C9 RU2015115529A RU2015115529A RU2693465C9 RU 2693465 C9 RU2693465 C9 RU 2693465C9 RU 2015115529 A RU2015115529 A RU 2015115529A RU 2015115529 A RU2015115529 A RU 2015115529A RU 2693465 C9 RU2693465 C9 RU 2693465C9
Authority
RU
Russia
Prior art keywords
grpr
group
des
chelating agent
composition according
Prior art date
Application number
RU2015115529A
Other languages
English (en)
Russian (ru)
Other versions
RU2015115529A (ru
RU2693465C2 (ru
Inventor
Теодосия МАИНА-НОК
Бертхольд Артур НОК
ЙОНГ ХЕНДРИКС Марион ДЕ
Original Assignee
ЭДВАНСТ ЭКСЕЛЕРЕЙТЕР ЭПЛИКЕЙШНС ЮЭсЭй, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭДВАНСТ ЭКСЕЛЕРЕЙТЕР ЭПЛИКЕЙШНС ЮЭсЭй, ИНК. filed Critical ЭДВАНСТ ЭКСЕЛЕРЕЙТЕР ЭПЛИКЕЙШНС ЮЭсЭй, ИНК.
Publication of RU2015115529A publication Critical patent/RU2015115529A/ru
Publication of RU2693465C2 publication Critical patent/RU2693465C2/ru
Application granted granted Critical
Publication of RU2693465C9 publication Critical patent/RU2693465C9/ru

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2015115529A 2012-09-25 2013-09-25 Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания RU2693465C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
US61/705,513 2012-09-25
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019119378A Division RU2821944C2 (ru) 2012-09-25 2013-09-25 Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания

Publications (3)

Publication Number Publication Date
RU2015115529A RU2015115529A (ru) 2016-11-20
RU2693465C2 RU2693465C2 (ru) 2019-07-03
RU2693465C9 true RU2693465C9 (ru) 2020-08-14

Family

ID=49887190

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015115529A RU2693465C9 (ru) 2012-09-25 2013-09-25 Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания

Country Status (19)

Country Link
US (7) US9839703B2 (enExample)
EP (2) EP2900279B1 (enExample)
JP (4) JP6562838B2 (enExample)
KR (2) KR102314293B1 (enExample)
AU (4) AU2013323596C1 (enExample)
BR (1) BR112015006453B1 (enExample)
CA (2) CA3114832A1 (enExample)
DK (1) DK2900279T3 (enExample)
ES (1) ES2745635T3 (enExample)
HR (1) HRP20191620T1 (enExample)
HU (1) HUE045724T2 (enExample)
IL (4) IL276300B2 (enExample)
LT (1) LT2900279T (enExample)
MX (1) MX362675B (enExample)
PL (1) PL2900279T3 (enExample)
PT (1) PT2900279T (enExample)
RU (1) RU2693465C9 (enExample)
SI (1) SI2900279T1 (enExample)
WO (1) WO2014052471A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449260B2 (en) * 2011-07-08 2019-10-22 Theodosia Maina-Nock Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
KR102314293B1 (ko) * 2012-09-25 2021-10-19 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
WO2018132751A1 (en) 2017-01-12 2018-07-19 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
WO2020074691A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
CN120081907A (zh) * 2018-11-13 2025-06-03 省卫生服务机构 用于胃泌素释放肽受体(grpr)的体内成像和治疗grpr相关病症的放射性标记蛙皮素衍生化合物
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
EP4031193A1 (en) * 2019-09-16 2022-07-27 Novartis AG Stable, concentrated radiopharmaceutical composition
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
US20230321287A1 (en) * 2019-09-24 2023-10-12 Novartis Ag Radiolabelled grpr-antagonist for use as theragnostic
BR112022010906A2 (pt) * 2019-12-19 2022-09-06 Univ Muenchen Tech Composto que se liga a um receptor endógeno, composição farmacêutica e de diagnóstico
JP2025510161A (ja) 2022-03-25 2025-04-14 プロビンシャル・ヘルス・サービシーズ・オーソリティ ガストリン放出ペプチド受容体(grpr)のインビボイメージング及びgrpr関連障害の治療のための放射性標識化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943561A (en) 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
WO1991006563A1 (en) 1989-11-06 1991-05-16 Farmitalia Carlo Erba S.R.L. Reduced irreversible bombesin antagonists
JPH07505865A (ja) 1992-02-07 1995-06-29 メレルダウファーマスーティカルズ インコーポレイテッド ボンベシンのフェニルアラニン類似体類
US5620955A (en) 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
AU2004259028C1 (en) 2003-07-24 2009-12-24 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for preparation
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EA026443B1 (ru) 2010-11-22 2017-04-28 Пирамаль Имэджинг Са Меченныелютецием аналоги бомбезина для лучевой терапии
US10449260B2 (en) * 2011-07-08 2019-10-22 Theodosia Maina-Nock Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
KR102314293B1 (ko) * 2012-09-25 2021-10-19 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABD-ELGALIEL W R ET AL., "Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vecto", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, 2008, vol. 19, no. 10, pages 2040-2048. *
DAVID C. HEIMBROOK ET AL., "Gastrin releasing peptide antagonists with improved potency and stability", JOURNAL OF MEDICINAL CHEMISTRY, 1991, vol. 34, no. 7, pages 2102-2107. *
DAVID C. HEIMBROOK ET AL., "Gastrin releasing peptide antagonists with improved potency and stability", JOURNAL OF MEDICINAL CHEMISTRY, 1991, vol. 34, no. 7, pages 2102-2107. SAFAVY ET AL., Synthesis of bombesin analogs for radiolabeling with rhenium-188 // CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, 1997, vol. 80, no. 12, pages 2354-2359. *
SAFAVY ET AL., Synthesis of bombesin analogs for radiolabeling with rhenium-188 // CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, 1997, vol. 80, no. 12, pages 2354-2359. *

Also Published As

Publication number Publication date
HUE045724T2 (hu) 2020-01-28
AU2018204513B2 (en) 2019-05-23
LT2900279T (lt) 2019-11-11
CA2886068A1 (en) 2014-04-03
KR102190005B1 (ko) 2020-12-15
AU2019216714A1 (en) 2019-09-05
JP2015533119A (ja) 2015-11-19
IL276300B1 (en) 2024-06-01
SI2900279T1 (sl) 2019-12-31
RU2019119378A (ru) 2020-10-23
AU2013323596C1 (en) 2020-10-15
JP2021191800A (ja) 2021-12-16
AU2018204513C1 (en) 2020-10-15
US20220008568A1 (en) 2022-01-13
KR20200139846A (ko) 2020-12-14
IL312551A (en) 2024-07-01
AU2013323596A1 (en) 2015-04-02
US20180133349A1 (en) 2018-05-17
US20240366812A1 (en) 2024-11-07
PL2900279T3 (pl) 2020-05-18
KR20150090886A (ko) 2015-08-06
MX362675B (es) 2019-01-30
US12064491B2 (en) 2024-08-20
IL312551B1 (en) 2025-08-01
RU2015115529A (ru) 2016-11-20
BR112015006453B1 (pt) 2023-10-17
US11083805B2 (en) 2021-08-10
JP7534498B2 (ja) 2024-08-14
MX2015003772A (es) 2015-11-09
PT2900279T (pt) 2019-10-14
IL256649A (en) 2018-02-28
US20200009276A1 (en) 2020-01-09
US12064490B2 (en) 2024-08-20
US20150265732A1 (en) 2015-09-24
DK2900279T3 (da) 2019-09-30
AU2018204513A1 (en) 2018-07-12
WO2014052471A1 (en) 2014-04-03
ES2745635T3 (es) 2020-03-03
EP2900279B1 (en) 2019-08-14
AU2021201914A1 (en) 2021-04-29
EP2900279A1 (en) 2015-08-05
IL312551B2 (en) 2025-12-01
IL256649B (en) 2020-08-31
JP7358430B2 (ja) 2023-10-10
JP2019167365A (ja) 2019-10-03
US20210346529A1 (en) 2021-11-11
US20210346528A1 (en) 2021-11-11
US9839703B2 (en) 2017-12-12
IL276300A (en) 2020-09-30
KR102314293B1 (ko) 2021-10-19
RU2693465C2 (ru) 2019-07-03
CA3114832A1 (en) 2014-04-03
JP2023126440A (ja) 2023-09-07
AU2013323596B2 (en) 2018-03-22
IL237844B (en) 2018-01-31
JP6997135B2 (ja) 2022-02-04
EP3536347A1 (en) 2019-09-11
HRP20191620T1 (hr) 2019-12-13
IL276300B2 (en) 2024-10-01
US12064489B2 (en) 2024-08-20
CA2886068C (en) 2021-06-22
AU2021201914B2 (en) 2024-09-05
BR112015006453A2 (enExample) 2017-09-05
AU2019216714B2 (en) 2021-04-08
JP6562838B2 (ja) 2019-08-21

Similar Documents

Publication Publication Date Title
JP7534498B2 (ja) Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
JP2020516676A (ja) 二重標的イメージング用分子プローブ及びその調製方法と応用
WO2011066521A2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
Gaonkar et al. Improving Affinity while Reducing Kidney Uptake of CXCR4‐Targeting Radioligands Derived from the Endogenous Antagonist EPI‐X4
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
TH4A Reissue of patent specification